OmniAb, Inc. 8-K

What Happened

• OmniAb, Inc. announced the appointment of Amechi Nwachuku as Chief Operating Officer, effective July 13, 2026. Mr. Nwachuku, age 51, joins with more than two decades of life‑sciences commercial leadership at companies including Thermo Fisher Scientific, SCIEX, Beckman Coulter, Johnson & Johnson and Bayer. He holds an M.B.A. from MIT Sloan and a B.S. in Chemical Engineering from MIT.
• In connection with his hire, OmniAb set Mr. Nwachuku’s initial annual base salary at $445,000, provided a $20,000 signing bonus, an annual target bonus opportunity equal to 45% of base salary (prorated for 2026), and granted stock options to purchase 800,000 shares effective August 1, 2026.

Key Details

• Base salary: $445,000; annual target bonus: 45% of base salary (prorated for 2026); signing bonus: $20,000.
• Equity: 800,000 stock options granted under the 2022 Incentive Award Plan; exercise price = Nasdaq closing price on grant date; vesting over four years with 12.5% vesting at six months and the remainder vesting in equal monthly installments thereafter.
• Severance Plan: involuntary termination without cause pays base salary for a severance period equal to two months plus one week per year of service, plus continued health coverage (COBRA), payable in a lump sum subject to a release.
• Change‑in‑control agreement: if terminated without cause or resigns for good reason within 24 months after a change in control, eligible for (1) 1× annual base salary, (2) 1× the greater of the maximum target bonus for the termination year or the change‑in‑control year, and (3) 12× monthly health premium; time‑based awards vest and option exercise window extended to nine months after termination (instead of three).

Why It Matters

• Leadership: Hiring an experienced commercial leader signals OmniAb’s focus on scaling operations and commercialization capabilities—relevant for investors watching execution and go‑to‑market progress.
• Compensation and dilution: The large option award (800,000 options) and cash/bonus commitments increase potential dilution and future compensation expense; exercise price will be set at the Nasdaq close on the grant date.
• Change‑in‑control and severance protections: The agreed severance and CIC protections provide executive retention and transition safeguards but represent potential cash and equity costs under certain scenarios. No financial results or other material transactions were reported in this filing.